{"url_path":"/sec/tnon/8-k/2026-06-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1560293/0001213900-26-067819-index.html","accession_number":"0001213900-26-067819","cik":"0001560293","ticker":"TNON","issuer_name":"Tenon Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1560293/0001213900-26-067819-index.html","primary_entity_key":"0001560293","primary_entity_name":"Tenon Medical, Inc."},"word_count":328,"has_tables":true,"body_markdown":"false\n--12-31\n0001560293\n\n0001560293\n\n2026-06-10\n2026-06-10\n\n0001560293\n\nTNON:CommonStockParValue0.001PerShareMember\n\n2026-06-10\n2026-06-10\n\n0001560293\n\nTNON:WarrantsMember\n\n2026-06-10\n2026-06-10\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n  \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n** **\n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**PURSUANT TO SECTION 13 OR 15(d)**\n\n**OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nDate of Report (Date of earliest event reported):\n\n**June 10, 2026**\n\n \n\n**TENON MEDICAL, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**001-41364**\n \n**45-5574718**\n\n(State or other jurisdiction\n \n(Commission File Number)\n \n(IRS Employer\n\nof incorporation)\n \n \n \nIdentification No.)\n\n \n\n**104 Cooper Court**\n \n \n\n**Los Gatos, CA**\n \n**95032**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n** **\n\n**(408) 649-5760**\n\n(Registrant’s telephone number, including\narea code)\n\n \n\n**N/A**\n\n(Former name or former address, if changed since\nlast report.)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):\n\n \n\n☐Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon\nStock, par value $0.001 per share\n \nTNON\n \nThe\nNasdaq Stock Market LLC\n\nWarrants\n \nTNONW\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\nGrowth Company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}